Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)
NCT07211776Phase 3Active, not recruiting
- Sponsor
- Zai Lab
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of elegrobart in thyroid eye disease (TED), sponsored by Zai Lab. Started Dec 2025; status: active, not recruiting.
02
Drugs
elegrobart
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07211776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211776.